If you're in the bull camp on CMLS, then I would look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $2.73 to $2.90 a share and then once it clears more overhead resistance at $3.12 to $3.13 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 222,979 shares. If that breakout triggers soon, then CMLS will set up to re-test or possibly take out its next major overhead resistance levels at $3.65 to $3.74 a share. Keep in mind that any move above $2.86 will then push CMLS back above its 200-day moving average, which s bullish technical price action.
The last name to consider with some huge insider buying is biotechnology and drugs player
. This company is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. Insiders are buying this stock into some big time weakness, since shares are off by 65% so far in 2012.
Catalyst Pharmaceuticals has a market cap of $15.06 million and an enterprise value of $3.67 million. This stock trades at a cheap valuation, with a price-to-book of 1.65. Its estimated growth rate for next quarter is 50%, and for this year it's pegged at 31%. This is a cash-rich company, since the total cash position on its balance sheet is $11.97 million and its total debt is zero.
A beneficial owner just
bought 5,000,000 shares, or about $3.75 million worth of stock, at 75 cents per share.
From a technical perspective, CPRX is currently trending well below both its 50-day and 200-day moving averages, which is bearish. This stock recently gapped down big from over $1.40 to close to 40 cents per share with heavy downside volume. Following that move, shares of CPRX have been trending sideways between 37 cents on the downside and 54 cents on the upside. A high-volume move outside of that range soon will likely lead to the next major trend for shares of CPRX.